ANGLE Announces Collaboration with Myriad Genetics
ANGLE plc (OTCQX:ANPCY) has announced a strategic collaboration with Myriad Genetics (NASDAQ:MYGN) to evaluate the feasibility of using Parsortix-derived circulating tumor cell (CTC) DNA with Myriad's existing tissue-based diagnostic tests.
Under the agreement, ANGLE's R&D team will process cancer patient blood samples using their Parsortix® system to capture intact cancer cells for molecular analysis. The study will compare CTC-DNA results with matched patient tissue samples using Myriad's current tissue-based assay. The specific terms of the agreement remain confidential between the parties.
ANGLE plc (OTCQX:ANPCY) ha annunciato una collaborazione strategica con Myriad Genetics (NASDAQ:MYGN) per valutare la fattibilità dell'impiego del DNA circolante derivato da cellule tumorali (CTC) ottenute con Parsortix nei test diagnostici tissutali già in uso da Myriad.
Secondo l'accordo, il team R&S di ANGLE processerà campioni di sangue di pazienti oncologici con il sistema Parsortix® per isolare cellule tumorali integre e analizzarne il materiale molecolare. Lo studio confronterà i risultati del DNA da CTC con quelli ottenuti da campioni tissutali corrispondenti analizzati con il test tissutale attuale di Myriad. I dettagli specifici dell'intesa restano riservati tra le parti.
ANGLE plc (OTCQX:ANPCY) ha anunciado una colaboración estratégica con Myriad Genetics (NASDAQ:MYGN) para evaluar la viabilidad de usar ADN de células tumorales circulantes (CTC) derivadas con Parsortix en las pruebas diagnósticas basadas en tejido que Myriad ya emplea.
Según el acuerdo, el equipo de I+D de ANGLE procesará muestras de sangre de pacientes con cáncer usando el sistema Parsortix® para capturar células tumorales intactas y analizarlas molecularmente. El estudio comparará los resultados del ADN de CTC con las muestras de tejido emparejadas de los pacientes evaluadas con el ensayo tisular actual de Myriad. Los términos concretos del acuerdo permanecen confidenciales entre las partes.
ANGLE plc (OTCQX:ANPCY)는 Myriad Genetics (NASDAQ:MYGN)와 전략적 협력을 맺고 Parsortix로 분리한 순환종양세포(CTC) 유래 DNA를 Myriad의 기존 조직 기반 진단검사에 적용할 수 있는지 평가하기로 했습니다.
계약에 따라 ANGLE의 연구개발팀은 Parsortix® 시스템을 사용해 암 환자의 혈액 샘플에서 완전한 종양세포를 회수하고 분자 분석을 실시합니다. 이 연구는 CTC 유래 DNA 결과를 동일 환자의 조직 샘플 결과와 Myriad의 현행 조직 검사로 비교할 예정입니다. 계약의 구체적 조건은 당사자 간 비공개로 유지됩니다.
ANGLE plc (OTCQX:ANPCY) a annoncé une collaboration stratégique avec Myriad Genetics (NASDAQ:MYGN) pour évaluer la faisabilité d'utiliser l'ADN dérivé de cellules tumorales circulantes (CTC) isolées par Parsortix avec les tests diagnostiques tissulaires existants de Myriad.
Dans le cadre de l'accord, l'équipe R&D d'ANGLE traitera des échantillons de sang de patients atteints de cancer avec le système Parsortix® afin de capturer des cellules tumorales intactes pour des analyses moléculaires. L'étude comparera les résultats de l'ADN issu des CTC avec des échantillons tissulaires appariés des patients analysés avec le test tissulaire actuel de Myriad. Les modalités précises de l'accord restent confidentielles entre les parties.
ANGLE plc (OTCQX:ANPCY) hat eine strategische Zusammenarbeit mit Myriad Genetics (NASDAQ:MYGN) angekündigt, um die Machbarkeit der Verwendung von Parsortix-abgeleiteter zirkulierender Tumorzell-DNA (CTC-DNA) in Myriads bestehenden gewebebasierten Diagnosetests zu prüfen.
Im Rahmen der Vereinbarung wird das F&E-Team von ANGLE Blutproben von Krebspatienten mit dem Parsortix®-System verarbeiten, um intakte Tumorzellen für molekulare Analysen zu gewinnen. Die Studie wird die CTC-DNA-Ergebnisse mit passenden Gewebeproben der Patienten vergleichen, die mit Myriads aktuellem Gewebetest untersucht wurden. Die konkreten Bedingungen der Vereinbarung bleiben zwischen den Parteien vertraulich.
- Collaboration with Myriad Genetics, a major player in tissue-based companion diagnostic tests
- Potential to improve access to actionable genomic data through simple blood tests
- Opportunity to expand Parsortix system's applications in clinical diagnostics
- Agreement terms and financial details not disclosed
- Currently limited to research use only, not approved for diagnostic procedures
Insights
ANGLE's partnership with Myriad Genetics could expand liquid biopsy applications, potentially creating significant new market opportunities.
ANGLE has formed a strategic collaboration with Myriad Genetics to evaluate the feasibility of using circulating tumor cell (CTC) DNA obtained through ANGLE's Parsortix system alongside Myriad's established tissue-based diagnostic tests. This partnership aims to compare CTC-DNA with matched patient tissue samples, potentially enabling blood-based alternatives to traditional tissue biopsies.
This collaboration holds significant strategic value for ANGLE. Myriad Genetics is a major player in molecular diagnostics with an established market presence and regulatory expertise. By partnering with Myriad, ANGLE gains validation from a recognized industry leader while potentially expanding the clinical applications of its Parsortix technology.
The partnership addresses a critical healthcare challenge: improving access to genomic data. Traditional tissue biopsies are invasive, costly, and sometimes impossible to obtain. A liquid biopsy alternative could dramatically expand patient access to precision medicine by offering a simpler, less invasive option that still provides actionable genomic information. This aligns with the growing trend toward minimally invasive diagnostic procedures.
While financial terms remain confidential, the commercial potential is substantial. If successful, this collaboration could position ANGLE's technology as an integral component in Myriad's diagnostic workflow, potentially generating significant recurring revenue through either licensing arrangements or increased Parsortix system adoption.
The announcement emphasizes that ANGLE's technology is currently for research use only, indicating regulatory approval would be needed before clinical implementation. This signals a longer-term development horizon before any commercial impact materializes, requiring investors to view this as an early-stage strategic positioning rather than an immediate revenue driver.
Assessment of feasibility for use of Parsortix derived circulating tumour cell (CTC) DNA with Myriad Genetics' existing tissue-based diagnostic test
GUILDFORD, SURREY / ACCESS Newswire / August 20, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is delighted to announce that it has entered a collaboration with Myriad Genetics, Inc. (MYGN:NSQ), a leading molecular diagnostic testing and precision medicine company dedicated to advancing health and well-being for all.
Under the terms of the agreement, blood samples from cancer patients will be processed by ANGLE's research and development team utilising the Parsortix® system for the capture and harvest of intact cancer cells for downstream molecular analysis. Results for this analysis will compare CTC-DNA with matched patient tissue samples using Myriad Genetics' existing tissue-based assay.
Further details of the agreement are confidential between the parties.
ANGLE Chief Executive, Andrew Newland, commented:
"We are delighted to be working with Myriad Genetics, a major player in tissue-based companion diagnostic tests, seeking to extend their tests to work on a simple blood test using CTCs harvested by the Parsortix system. We look forward to working with Myriad Genetics to progress this collaboration which has the potential to have a substantial impact on patient treatment by improving access to actionable genomic data."
For further information:
ANGLE plc | +44 (0) 1483 343434 |
Andrew Newland, Chief Executive Ian Griffiths, Finance Director | |
Berenberg (NOMAD and Broker) Toby Flaux, Ciaran Walsh, Milo Bonser | +44 (0) 20 3207 7800 |
FTI Consulting Simon Conway, Ciara Martin Matthew Ventimiglia (US) | +44 (0) 203 727 1000 +1 (212) 850 5624 |
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the EU Market Abuse Regulation (596/2014).Upon the publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
For Research Use Only. Not for use in diagnostic procedures.
For Frequently Used Terms, please see the Company's website on https://angleplc.com/investor-relations/glossary/
Notes for editors
About ANGLE plc
ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's FDA cleared and patent protected circulating tumour cell (CTC) harvesting technology known as the Parsortix® PC1 System enables complete downstream analysis of the sample including whole cell imaging and proteomic analysis and full genomic and transcriptomic molecular analysis.
ANGLE's commercial businesses are focusing on diagnostic products and clinical services. Diagnostic products include the Parsortix® system, associated consumables and assays. The clinical services business is offered through ANGLE's GCLP-compliant laboratories. Services include custom made assay development and clinical trial testing for pharma.
Over 110 peer-reviewed publications have demonstrated the performance of the Parsortix system. For more information, visit www.angleplc.com
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
SOURCE: ANGLE plc
View the original press release on ACCESS Newswire
FAQ
What is the purpose of ANGLE's collaboration with Myriad Genetics?
How will ANGLE (ANPCY) process the samples in this collaboration?
What are the potential benefits of this ANGLE-Myriad Genetics partnership?
Is ANGLE's Parsortix system currently approved for diagnostic use?
What are the financial terms of the ANGLE-Myriad collaboration agreement?
